FBIO (Fortress Biotech) Scaled Net Operating Assets: 0.00 (As of Mar. 2026)


FBIO Fortress Biotech Inc FBIO
44 GF Score
Price $2.74
GF Value $1.23
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Fortress Biotech Scaled Net Operating Assets?

Fortress Biotech FBIO -8.61% 44 Scaled Net Operating Assets is 0.00 as of Mar. 2026. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.23 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Fortress Biotech's operating assets for the quarter that ended in Mar. 2026 was $101.03 Mil. Fortress Biotech's operating liabilities for the quarter that ended in Mar. 2026 was $100.87 Mil. Fortress Biotech's Total Assets for the quarter that ended in Dec. 2025 was $185.55 Mil. Therefore, Fortress Biotech's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.00.


Fortress Biotech Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Scaled Net Operating Assets Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.00 0.02 0.10 0.40

Fortress Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.18 0.30 0.32 0.00

FBIO vs PTHS, IBIO, NRXS: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Fortress Biotech's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Scaled Net Operating Assets falls into.


FBIO
44GF Score
Fortress Biotech Inc FBIO
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Fortress Biotech's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(106.167-49.064)/144.223
=0.40

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=185.548 - 79.381
=106.167

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=123.365 - 72.174 - 2.127
=49.064

Fortress Biotech's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(101.033-100.873)/185.548
=0.00

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=356.874 - 255.841
=101.033

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=154.5 - 48.906 - 4.721
=100.873

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.00 mean?
Fortress Biotech (FBIO) has a Scaled Net Operating Assets of 0.00 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Fortress Biotech and its competitors.
Is Fortress Biotech's Scaled Net Operating Assets too high?
Fortress Biotech's current Scaled Net Operating Assets is 0.00. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Scaled Net Operating Assets compare to PTHS and IBIO?
Fortress Biotech's Scaled Net Operating Assets of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current Scaled Net Operating Assets is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $2.74 — trading 122.8% above its estimated fair value. The current Scaled Net Operating Assets is 0.00. Fortress Biotech's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Scaled Net Operating Assets is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortress Biotech (FBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of $2.74 is trading 122.8% above its estimated GF Value™ of $1.23. GuruFocus considers Fortress Biotech to be Significantly Overvalued.

Key valuation signals for FBIO:

  • Scaled Net Operating Assets: 0.00
  • GF Value™: $1.23 vs. price of $2.74 (122.8% above fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score

Get the complete analysis for FBIO

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$1.23
GF Value